Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments

Gynecol Oncol. 1999 Feb;72(2):232-7. doi: 10.1006/gyno.1998.5251.


Purpose: With a retrospective study at a single institution, we propose to analyze the prognosis factors and adjuvant treatment for uterine sarcomas.

Materials and methods: From 1975 to 1995, 73 uterine sarcomas were treated at the Institut Curie, corresponding to 61 T1, 5 T2, and 8 T4 tumors. Thirteen patients had metastatic disease at the time of diagnosis. The mean age was 58 years. In 71% of patients, the presenting sign was bleeding. This series consisted of 44% leiomyosarcomas (LMS), 19% endometrial stromal sarcomas (ESS), and 31% carcinosarcomas or mixed mesodermal sarcomas (MMS). For the grading classification, we used the classification of the Sarcoma Group of the French Federation of Cancer Centres for soft tissue sarcomas. Of the patients, 66% presented a high-grade tumor.

Results: The median overall survival was 42 months, with a 5-year survival of 45%. Histological grade, FIGO stage, histology types, and menopausal status were the four independent factors in multivariate analysis. Eighteen patients relapsed locally (25.7%), with 77% central pelvic sites. Patients with radiotherapy and ESS had better local control in multivariate analysis. Thirty-four patients developed metastases (48.6%), mainly pulmonary (58.8%). Eight patients presented with peritoneal disease. High grades and LMS had the worst survival without metastasis in multivariate analysis.

Conclusion: This study validated our classification for sarcoma grading and confirmed the finding of worst prognosis for LMS and the importance of radiotherapy in local control.

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Female
  • Humans
  • Medical Records
  • Menopause
  • Middle Aged
  • Prognosis
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Sarcoma / classification*
  • Sarcoma / mortality
  • Sarcoma / therapy*
  • Survival Analysis
  • Uterine Neoplasms / classification*
  • Uterine Neoplasms / mortality
  • Uterine Neoplasms / therapy*